Tech Company Financing Transactions
DiCE Molecules Funding Round
RA Capital, Sands Capital Management and Asymmetry Capital Management participated in a $60 million Series C funding round for DiCE Molecules. The round was announced on 8/25/2021.
Transaction Overview
Company Name
Announced On
8/25/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to advance: advance its preclinical IL-17 antagonist franchise into clinical development, advance its preclinical a4ß7 and aVß1/aVß6 integrin programs, expand its pipeline, and for other general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
279 E. Grand Ave. Lobby B 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Judice
Chief Financial Officer
Scott Robertson
Chief Medical Officer
Timothy Lu
Vice President
Paul Fatheree
Vice President
Nico Ghilardi
Vice President
John Jacobsen
Vice President
Meina Tang
Browse more venture capital transactions:
Prev: 8/25/2021: CapShift venture capital transaction
Next: 8/25/2021: Sora venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs